Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Sankt Augustin – page 6

1 118 clinical trials in Sankt Augustin, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Sankt Augustin at a glance
1 118
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 118 trials in Sankt Augustin

Open in trial search

Non-small cell lung cancer

Recruiting

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Astrazeneca AB

Non-small cell lung cancer stage IV+2

Recruiting

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Malignant melanoma

Recruiting

Study on IMA203 for Patients with Previously Treated Unresectable or Metastatic Skin Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immatics US Inc.

Hepatocellular carcinoma+1

Recruiting

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Chronic lymphocytic leukaemia+3

Recruiting

Study on the Safety and Effectiveness of AZD0486 Alone or with Other Drugs for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, or Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Astrazeneca AB

Non-small cell lung cancer

Recruiting

Study of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Acquired haemophilia

Recruiting

Evaluating denecimig as bleeding prophylaxis in adults with acquired haemophilia A

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Denecimig
  • Sponsor:Novo Nordisk A/S

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Neoplasm malignant

Recruiting

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Type 1 diabetes mellitus

Recruiting

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

HIV infection

Recruiting

Safety and efficacy of GS-3242 drug combination compared with standard drug combination in treatment‑naive adults with HIV‑1

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years · Healthy volunteers
  • Substances:GSKVX000000077430
  • Sponsor:GlaxoSmithKline Biologicals

Other cities in Germany

The busiest research cities in the country

All 506 cities in Germany

Clinical research in Sankt Augustin

What the registry says about research in the country

01 Pediatric Rheumatology

Clinical trials focusing on innovative treatments for juvenile arthritis conditions, including studies of medications like baricitinib, ustekinumab, and bimekizumab for various forms of JIA.

  • Juvenile Psoriatic Arthritis
  • Systemic Juvenile Idiopathic Arthritis
  • Enthesitis-related Arthritis

Research aims to evaluate drug efficacy and safety in pediatric populations with autoimmune conditions.

02 Pediatric Oncology

Comprehensive studies on childhood cancers, with particular focus on leukemia and lymphoma treatments, including novel therapeutic approaches and combination therapies.

  • Acute Lymphoblastic Leukemia
  • B-cell Lymphoma
  • Myeloid Leukemia

Investigations include targeted therapies and personalized treatment protocols for various cancer stages.

03 Neuro-Oncology

Specialized research into brain and nervous system tumors, focusing on ependymoma and medulloblastoma treatment strategies.

  • Medulloblastoma
  • Intracranial Ependymoma
  • Neuroblastoma

Studies evaluate surgical outcomes, radiation therapy approaches, and chemotherapy effectiveness.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.